keyword
MENU ▼
Read by QxMD icon Read
search

Diffuse large cell lymphoma

keyword
https://www.readbyqxmd.com/read/28549038/use-of-smooth-muscle-myosin-heavy-chain-as-an-effective-marker-of-follicular-dendritic-cells
#1
Ioannis Ioannidis, Javier A Laurini
Smooth muscle myosin heavy chain (SMMHC) is a major structural component of the contractile apparatus in smooth muscle cells. Even though it is considered a relatively specific marker for terminal smooth muscle cell differentiation, expression in other cell types such as follicular dendritic cells (FDCs) has rarely been reported. To determine whether SMMHC represents an effective FDC marker in lymphoid tissues, we compared the immunohistochemical results for SMMHC with those of the traditional FDC markers podoplanin (D2-40) and CD21...
May 25, 2017: Applied Immunohistochemistry & Molecular Morphology: AIMM
https://www.readbyqxmd.com/read/28548962/prognostic-implication-of-leucocyte-subpopulations-in-diffuse-large-b-cell-lymphoma
#2
Xiao Han, Jing Ruan, Wei Zhang, Daobin Zhou, Dongsheng Xu, Qiang Pei, Mingqi Ouyang, Mengxuan Zuo
BACKGROUND: Recent studies have suggested that variables related to host adaptive immunity and the tumor microenvironment may predict the outcome in patients with non-Hodgkin's lymphoma. This study was undertaken to determine the prognostic value of peripheral blood leucocyte subpopulations in diffuse large-B-cell lymphoma patients. METHODS: We prospectively analyzed the 16 leukocyte subpopulations using Cytodiff flow cytometric technique in a cohort of 45 diffuse large-B-cell lymphoma patients at a single institution between February and December 2014...
May 12, 2017: Oncotarget
https://www.readbyqxmd.com/read/28548080/discovery-of-first-in-class-reversible-dual-small-molecule-inhibitors-against-g9a-and-dnmts-in-hematological-malignancies
#3
Edurne San José-Enériz, Xabier Agirre, Obdulia Rabal, Amaia Vilas-Zornoza, Juan A Sanchez-Arias, Estibaliz Miranda, Ana Ugarte, Sergio Roa, Bruno Paiva, Ander Estella-Hermoso de Mendoza, Rosa María Alvarez, Noelia Casares, Victor Segura, José I Martín-Subero, François-Xavier Ogi, Pierre Soule, Clara M Santiveri, Ramón Campos-Olivas, Giancarlo Castellano, Maite Garcia Fernandez de Barrena, Juan Roberto Rodriguez-Madoz, Maria José García-Barchino, Juan Jose Lasarte, Matias A Avila, Jose Angel Martinez-Climent, Julen Oyarzabal, Felipe Prosper
The indisputable role of epigenetics in cancer and the fact that epigenetic alterations can be reversed have favoured development of epigenetic drugs. In this study, we design and synthesize potent novel, selective and reversible chemical probes that simultaneously inhibit the G9a and DNMTs methyltransferase activity. In vitro treatment of haematological neoplasia (acute myeloid leukaemia-AML, acute lymphoblastic leukaemia-ALL and diffuse large B-cell lymphoma-DLBCL) with the lead compound CM-272, inhibits cell proliferation and promotes apoptosis, inducing interferon-stimulated genes and immunogenic cell death...
May 26, 2017: Nature Communications
https://www.readbyqxmd.com/read/28544905/high-serum-levels-of-soluble-interleukin-2-receptor-sil2-r-interleukin-6-il-6-and-tumor-necrosis-factor-alpha-tnf-are-associated-with-adverse-clinical-features-and-predict-poor-outcome-in-diffuse-large-b-cell-lymphoma
#4
Ivan Dlouhy, Xavier Filella, Jordina Rovira, Laura Magnano, Alfredo Rivas-Delgado, Tycho Baumann, Alejandra Martínez-Trillos, Olga Balagué, Antonio Martínez, Blanca González-Farre, Kennosuke Karube, Eva Gine, Julio Delgado, Elías Campo, Armando López-Guillermo
Diffuse large B-cell lymphoma (DLBCL) is an aggressive lymphoma with heterogeneous outcomes. To improve accuracy of the international prognostic index score, new biological variables are being investigated. The aim of this study was to determine the prognostic significance of serum levels of different cytokines, namely soluble interleukin-2 receptor (sIL2-R), interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF). We analyzed 197 de novo DLBCL patients (91 M/106 F; median age 66 years) treated with immunochemotherapy in a single institution...
May 17, 2017: Leukemia Research
https://www.readbyqxmd.com/read/28543967/central-nervous-system-involvement-of-primary-cutaneous-diffuse-large-b-cell-lymphoma-leg-type-13-cases
#5
E Gardette, A Maraval, F Brunet-Possenti, G Quereux, H Beltraminelli, I Templier, J Hodel, E Scherman, E Durot, M Bagot, A Pham-Ledard, F Grange, M Beylot-Barry, S Ingen-Housz-Oro
Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT) is an aggressive primary cutaneous B-cell lymphoma affecting older people.(1) Rituximab (RTX) combined with polychemotherapy (RTX-PCT) has improved survival but relapses are frequent.(2) Central nervous system (CNS) involvement is rare and poorly described. This article is protected by copyright. All rights reserved.
May 23, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28542862/subsequent-primary-malignancies-after-diffuse-large-b-cell-lymphoma-in-the-modern-treatment-era
#6
Li Tao, Christina A Clarke, Aaron S Rosenberg, Ranjana H Advani, Brian A Jonas, Christopher R Flowers, Theresa H M Keegan
With the addition of rituximab and other treatment advances, survival after diffuse large B-cell lymphoma (DLBCL) has improved, but subsequent primary malignancies (SPMs) have emerged as an important challenge for DLBCL survivorship. We calculated standardized incidence ratios (SIRs) and 95% confidence intervals (CIs) for SPMs among 23 879 patients who survived at least 1 year after a first primary DLBCL diagnosed during 1989-2012, compared to the general population in California. Cumulative incidence (CMI) of SPMs, accounting for the competing risk of death, also was calculated...
May 25, 2017: British Journal of Haematology
https://www.readbyqxmd.com/read/28541555/effective-chemomobilization-with-etoposide-and-cytarabine-ec-regimen-in-lymphoma-patients-a-single-center-retrospective-observational-study
#7
Daisuke Koyama, Satoshi Nishiwaki, Yasuhiko Harada, Satomi Yamamoto, Shingo Kurahashi, Takumi Sugimoto, Toshihiro Iwasaki, Isamu Sugiura
Objective: Autologous stem cell transplantation is an important strategy for patients with relapsed or refractory lymphoma. Although various regimens for peripheral blood stem cell collection have been used, the optimal regimen has not yet been established. We aimed to evaluate the mobilization efficacy and safety of the regimen consisted of etoposide and cytarabine (EC regimen). Methods: We retrospectively analyzed the clinical data of 46 lymphoma patients who received peripheral blood stem cell mobilization with the EC regimen [etoposide (100 mg/m2/day, days 1-4) and cytarabine (100 mg/m2/day, days 1-4)] at Toyohashi municipal hospital from 2004 to 2013...
May 24, 2017: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28541439/the-evolutionary-landscape-of-dbl-like-rhogef-families-adapting-eukaryotic-cells-to-environmental-signals
#8
Philippe Fort, Anne Blangy
The dynamics of cell morphology in eukaryotes is largely controlled by small GTPases of the Rho family. Rho GTPases are activated by Guanine nucleotide Exchange Factors (RhoGEFs), of which Diffuse B-cell Lymphoma (Dbl)-like members form the largest family. Here we surveyed Dbl-like sequences from 175 eukaryotic genomes and illuminate how the Dbl family evolved in all eukaryotic supergroups. By combining probabilistic phylogenetic approaches and functional domain analysis, we show that the human Dbl-like family is made of 71 members, structured into 20 subfamilies...
May 25, 2017: Genome Biology and Evolution
https://www.readbyqxmd.com/read/28540907/oliguric-acute-kidney-injury-as-initial-presentation-of-renal-non-hodgkin-s-lymphoma-infiltration
#9
Tacyano T Leite, Alexandre B Libório, Geraldo B Silva Junior, Elizabeth De Francesco Daher
We report a case of a 20-year-old man presented to the emergency department with oliguria and renal failure requiring urgent dialysis. An ultrasound revealed enlarged kidneys, and a renal biopsy showed non-Hodgkin's lymphoma, subtype diffuse large B-cell.
May 2017: Saudi Journal of Kidney Diseases and Transplantation
https://www.readbyqxmd.com/read/28537908/increased-expression-of-irf8-in-tumor-cells-inhibits-the-generation-of-th17-cells-and-predicts-unfavorable-survival-of-diffuse-large-b-cell-lymphoma-patients
#10
Weijie Zhong, Xin Xu, Zhigang Zhu, Qinghua Du, Hong Du, Li Yang, Yanying Ling, Huabao Xiong, Qingshan Li
The immunological pathogenesis of diffuse large B cell lymphoma (DLBCL) remains elusive. Searching for new prognostic markers of DLBCL is a crucial focal point for clinical scientists. The aim of the present study was to examine the prognostic value of interferon regulatory factor 8 (IRF8) expression and its effect on the development of Th17 cells in the tumor microenvironment of DLBCL patients. Flow cytometry, immunohistochemistry, and quantitative real-time PCR were used to detect the distribution of Th17 cells and related cytokines and IRF8 in tumor tissues from DLBCL patients...
May 8, 2017: Oncotarget
https://www.readbyqxmd.com/read/28537882/correlation-between-apparent-diffusion-coefficient-adc-and-cellularity-is-different-in-several-tumors-a-meta-analysis
#11
Alexey Surov, Hans Jonas Meyer, Andreas Wienke
The purpose of this meta-analysis was to provide clinical evidence regarding relationship between ADC and cellularity in different tumors based on large patient data.Medline library was screened for associations between ADC and cell count in different tumors up to September 2016. Only publications in English were extracted. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement (PRISMA) was used for the research.Overall, 39 publications with 1530 patients were included into the analysis...
May 10, 2017: Oncotarget
https://www.readbyqxmd.com/read/28535584/molecular-testing-of-lymphoproliferative-disorders-current-status-and-perspectives
#12
REVIEW
Yoon Kyung Jeon, Sun Och Yoon, Jin Ho Paik, Young A Kim, Bong Kyung Shin, Hyun-Jung Kim, Hee Jeong Cha, Ji Eun Kim, Jooryung Huh, Young-Hyeh Ko
Molecular pathologic testing plays an important role for the diagnosis, prognostication and decision of treatment strategy in lymphoproliferative disease. Here, we briefly review the molecular tests currently used for lymphoproliferative disease and those which will be implicated in clinical practice in the near future. Specifically, this guideline addresses the clonality test for B- and T-cell proliferative lesions, molecular cytogenetic tests for malignant lymphoma, determination of cell-of-origin in diffuse large B-cell lymphoma, and molecular genetic alterations incorporated in the 2016 revision of the World Health Organization classification of lymphoid neoplasms...
May 2017: Journal of Pathology and Translational Medicine
https://www.readbyqxmd.com/read/28535082/evaluating-early-interim-fluorine-18-fluorodeoxyglucose-positron-emission-tomography-computed-tomography-with-the-suvmax-liver-based-interpretation-for-predicting-the-outcome-in-diffuse-large-b-cell-lymphoma
#13
Yang Fan, Yuewei Zhang, Zhi Yang, Zhitao Ying, Nina Zhou, Chen Liu, Yuqin Song, Jun Zhu, Xuejuan Wang
Interim (18)F-FDG PET/CT is an effective predictor in patients with DLBCL, but the standard evaluating criteria were controversial. In this study, investigators tried to investigate whether the liver SUVmax (SUVmax-liver)-based interpretation could improve the accuracy of predicting the outcomes, comparing with the Deauville five-point scale (5-PS) and the reduction rate of the maximum standardized uptake value (ΔSUVmax) criteria. In 119 patients, PET/CT after two chemotherapy cycles (PET2) were evaluated with the SUVmax-liver-based interpretation, 5-PS, and ΔSUVmax criteria...
May 23, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28533834/-splenic-marginal-zone-lymphoma
#14
Sinaa Mohamed
Splenic marginal zone lymphoma (SMZL) is a rare B-cell lymphoma, well defined according to the 2016 WHO classification of tumors of the hematopoietic tissue, which can raise diagnostic problems. We report the case of a 72-year old patient, hospitalised for exploration of a massive splenomegaly confirmed by computed tomography (CT). Laboratory tests were normal. The patient underwent splenectomy. Microscopic examination of the surgical specimen showed widespread lymphomatous proliferation in small cells associated with CD20 marker...
2017: Pan African Medical Journal
https://www.readbyqxmd.com/read/28525457/stensen-duct-relapse-of-diffuse-large-b-cell-lymphoma-an-unusual-pattern-detected-with-18f-fdg-pet-ct
#15
Punit Sharma, Shilpa Bhartia
F-FDG PET/CT is now an established modality for staging and restaging high-grade lymphomas, including diffuse large B-cell lymphoma. We here present the case of a 51-year-old woman successfully treated for diffuse large B-cell lymphoma. Follow-up F-FDG PET/CT demonstrated an unusual site of relapse involving left Stensen (parotid) duct, which was confirmed with cytology. By identifying such unusual sites of lymphomatous involvement, F-FDG PET/CT can have significant bearing on patient management.
May 19, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28525305/clinical-impact-of-the-cell-of-origin-classification-and-the-myc-bcl2-dual-expresser-status-in-diffuse-large-b-cell-lymphoma-treated-within-prospective-clinical-trials-of-the-german-high-grade-non-hodgkin-s-lymphoma-study-group
#16
Annette M Staiger, Marita Ziepert, Heike Horn, David W Scott, Thomas F E Barth, Heinz-Wolfram Bernd, Alfred C Feller, Wolfram Klapper, Monika Szczepanowski, Michael Hummel, Harald Stein, Dido Lenze, Martin-Leo Hansmann, Sylvia Hartmann, Peter Möller, Sergio Cogliatti, Georg Lenz, Lorenz Trümper, Markus Löffler, Norbert Schmitz, Michael Pfreundschuh, Andreas Rosenwald, German Ott
Purpose To explore the prognostic impact and interdependence of the cell-of-origin (COO) classification, dual expression (DE) of MYC and BCL2 proteins, and MYC, BCL2, and BCL6 translocations in two prospectively randomized clinical trials of patients with diffuse large B-cell lymphoma (DLBCL). Patients and Methods Overall, 452 formalin-fixed paraffin-embedded samples from two prospective, randomized DLBCL trials (RICOVER-60, prospective, randomized study for patients > 60 years, all IPI groups; and R-MegaCHOEP, prospective, randomized study for patients ≤ 60 years with age-adjusted IPI 2,3) of the German High-Grade Non-Hodgkin Lymphoma Study Group were analyzed with the Lymph2Cx assay for COO classification, with immunohistochemistry for MYC and BCL2, and with fluorescent in situ hybridization for MYC, BCL2, and BCL6 rearrangements...
May 19, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28524259/nonpegylated-liposomal-doxorubicin-combination-regimen-in-patients-with-diffuse-large-b-cell-lymphoma-and-cardiac-comorbidity-results-of-the-heart01-phase-ii-trial-conducted-by-the-fondazione-italiana-linfomi
#17
Stefano Luminari, Elda Viel, Andrés José Maria Ferreri, Francesco Zaja, Emanuela Chimienti, Gerardo Musuraca, Alessandra Tucci, Monica Balzarotti, Monica Tani, Francesca Salvi, Emanuela A Pesce, Angela Ferrari, Anna M Liberati, Antonio Spadea, Dario Marino, Maria Bruno-Ventre, Stefano Volpetti, Chiara Bottelli, Elena Ravaioli, Francesco Merli, Michele Spina
The purpose of this phase 2, multicenter study was to determine the activity and safety of nonpegylated liposomal doxorubicin as part of "R-COMP" combination in patients with diffuse large B-cell lymphoma and coexisting cardiac disorders. The study was conducted using a Bayesian continuing assessment method using complete remission rate and rate of cardiac events as study endpoints. Between November 2009 and October 2011, 50 evaluable patients were enrolled (median age, 76 years). Median baseline left ventricular ejection fraction (LVEF) was 60%...
May 19, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28522442/bcl2-expression-in-dlbcl-reappraisal-of-immunohistochemistry-with-new-criteria-for-therapeutic-biomarker-evaluation
#18
Naoko Tsuyama, Seiji Sakata, Satoko Baba, Yuko Mishima, Noriko Nishimura, Kyoko Ueda, Masahiro Yokoyama, Yasuhito Terui, Kiyohiko Hatake, Masanobu Kitagawa, Naoki Ishizuka, Naoto Tomita, Kengo Takeuchi
Overexpression of the BCL2 is associated with a poor prognosis in diffuse large B-cell lymphoma (DLBCL). The assessment of MYC immunohistochemistry (IHC) is becoming optimized, whereas the criteria for BCL2 positivity are highly variable. Furthermore, data on the frequency and prognostic value of BCL2 positivity are conflicting. We aimed to evaluate BCL2 expression by IHC and assess the prognostic significance of the histopathologically-scored BCL2 expression in 456 patients with DLBCL uniformly treated with standard immunochemotherapy (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CHOP)...
May 18, 2017: Blood
https://www.readbyqxmd.com/read/28521633/cd30-expression-in-pediatric-neoplasms-study-of-585-cases
#19
Jinjun Cheng, Haiqing Zhu, John Kim Choi
CD30 is a member of the tumor necrosis factor receptor superfamily, member 8 (TNFRSF8), and its normal expression is restricted to activated T and B cells. In tumor cells, CD30 expression is most commonly associated with lymphoid malignancies (Hodgkin and non-Hodgkin lymphomas) and is a therapeutic target using anti-CD30 antibody. CD30 expression has been reported also in mostly adult non-lymphoid malignancies, raising the possibility of CD30-targeted therapy for additional tumors. In this study, we examined the incidence of CD30 expression in 251 hematopoietic and 334 non-hematopoietic cases of pediatric tumors...
June 2017: Pediatric and Developmental Pathology
https://www.readbyqxmd.com/read/28515935/methotrexate-encephalopathy-two-cases-in-adult-cancer-patients-who-recovered-with-pathophysiologically-based-therapy
#20
Shodeinde A Coker, David A Pastel, Melissa C Davis, Elizabeth M Bengtson, Camilo E Fadul, Lionel D Lewis
BACKGROUND/OBJECTIVES: Neurotoxicity is a serious and sometimes fatal adverse effect that can occur following methotrexate treatment. We describe two adult patients with hematological malignancies with methotrexate encephalopathy who recovered with dextromethorphan therapy. RESULTS: Case 1: A 24-year-old male with acute lymphoblastic leukemia developed the acute onset of bilateral facial weakness and slurred speech after his first treatment with high-dose intravenous methotrexate...
2017: SAGE open medical case reports
keyword
keyword
6710
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"